BridgeMD
New treatment option for Femoral Access Site Closure
Official title Time to Ambulation After ProGlide Closure
ClinicalTrials.gov ID: NCT07179536
What this study is testing
- What it's testing
- Transradial access has become the standard for coronary procedures due to fewer vascular complications and shorter bed rest, yet transfemoral access remains essential for complex peripheral interventions requiring larger sheaths and stronger support. Vascular closure devices (VCDs), particularly suture-mediated devices such as ProGlide, have improved femoral access by reducing hemostasis time, ambulation delay, and patient discomfort.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Scheduled for peripheral angiography or endovascular intervention via transfemoral access.
- Femoral artery puncture site located at the common femoral artery.
- Use of 6-8F vascular sheath.
- Hemostasis achieved with 6F ProGlide closure device (defined as no active bleeding, no hematoma formation, and no ischemia of the punctured limb...
- Preoperative ankle-brachial index (ABI) \> 0.9 on both sides.
You likely can't join if
- Undergoing carotid artery intervention.
- Femoral artery diameter \< 5 mm, or effective lumen \< 5 mm due to plaque burden.
- History of vascular complications at the puncture site.
- Abnormal cardiopulmonary function.
- Intraoperative platelet count \< 80 × 10⁹/L, or use of thrombolytic agents.
- Cognitive impairment, uncooperative, or limited lower limb mobility.
See the full eligibility criteria
- Scheduled for peripheral angiography or endovascular intervention via transfemoral access.
- Femoral artery puncture site located at the common femoral artery.
- Use of 6-8F vascular sheath.
- Hemostasis achieved with 6F ProGlide closure device (defined as no active bleeding, no hematoma formation, and no ischemia of the punctured limb after closure).
- Preoperative ankle-brachial index (ABI) \> 0.9 on both sides.
- Conscious, cooperative, and with normal lower limb mobility.
- Undergoing carotid artery intervention.
- Femoral artery diameter \< 5 mm, or effective lumen \< 5 mm due to plaque burden.
- History of vascular complications at the puncture site.
- Abnormal cardiopulmonary function.
- Intraoperative platelet count \< 80 × 10⁹/L, or use of thrombolytic agents.
- Cognitive impairment, uncooperative, or limited lower limb mobility.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.